Table 3.

Treatment-related adverse events of bortezomib-based regimens.

Adverse events	VD (n = 79)	VDD (n = 58)	P-value
Hematologic events (Grade 3/4)	14 (17.7%)	23 (39.7%)	0.004
Neutropenia	2 (2.5%)	9 (15.5%)	0.006
Thrombocytopenia	8 (10.1%)	11 (19.0%)	0.139
Anemia	4 (5.1%)	3 (5.2%)	0.977
Cardiotoxicity	8 (10.1%)	4 (6.9%)	0.509
Arrhythmia	4 (5.1%)	0 (0.0%)	0.082
Heart failure	3 (3.8%)	2 (3.4%)	0.914
Left ventricular systolic dysfunction	0 (0.0%)	1 (1.7%)	0.241
ECG QT corrected interval prolonged	1 (1.3%)	1 (1.7%)	0.825
Infection	30 (38.0%)	36 (62.1%)	0.005
Pneumonia	30 (38.0%)	33 (56.9%)	0.028
Urinary tract	0 (0.0%)	3 (5.2%)	0.041
Thromboembolism	2 (2.5%)	0 (0.0%)	0.222
Deep vein thrombosis	1 (1.3%)	0 (0.0%)	0.390
Pulmonary embolus	1 (1.3%)	0 (0.0%)	0.390
Gastrointestinal	18 (22.8%)	27(46.6%)	0.003
Vomiting	1 (1.3%)	4 (6.9%)	0.082
Diarrhea	8 (10.1%)	15 (25.9%)	0.015
Abdominal distension	6 (7.6%)	4 (6.9%)	0.877
Intestinal obstruction	3 (3.8%)	4 (6.9%)	0.416
Hepatic disorders	4 (5.1%)	4 (6.9%)	0.651
Skin	21 (26.6%)	13 (22.4%)	0.577
Herpes zoster	13 (16.5%)	8 (13.8%)	0.669
Rash	8 (10.1%)	5 (8.6%)	0.766
Peripheral neuropathy	21 (26.6%)	16 (27.6%)	0.896

ECG, electrocardiogram.